Institution
Catholic University of the Sacred Heart
Education•Milan, Lombardia, Italy•
About: Catholic University of the Sacred Heart is a education organization based out in Milan, Lombardia, Italy. It is known for research contribution in the topics: Population & Health care. The organization has 13592 authors who have published 31048 publications receiving 853961 citations.
Topics: Population, Health care, Cancer, Myocardial infarction, Transplantation
Papers published on a yearly basis
Papers
More filters
••
University of Milan1, University of Rome Tor Vergata2, University of Bologna3, University of Brescia4, Sapienza University of Rome5, University of Sassari6, University of Bari7, University of Florence8, University of Padua9, European Institute of Oncology10, Catholic University of the Sacred Heart11
TL;DR: Follow-up and/or treatment of endometrial polyps incidentally diagnosed in asymptomatic postmenopausal patients could be safely restricted to few selected cases based on polyp diameter.
177 citations
••
TL;DR: This review summarizes the advance in reducing the impact of aflatoxins in different countries where peanuts are cultivated and proposes a single strategy to solve this problem.
177 citations
••
TL;DR: These properties suggest that the S-100 cells in the pituitary gland are neuroectodermal in origin, possibly glial in nature.
Abstract: The brain-specific S-100 protein was localized at the electron microscopic level in the anterior and posterior pituitary gland of adult rat by indirect immunoperoxidase histology. The protein was found in the stellate cells of the pars distalis and tuberalis, in the marginal cells that line the hypophyseal cleft and in the glia-like cells, the pituicytes, of the neural lobe. The pituicytes, the stellate cells and the marginal cells have in common at least two properties: they all express a brain-specific marker and they are satellite cells to the secretory axons in the neural lobe and of the secretory cells in the adenohypophysis. These properties suggest that the S-100 cells in the pituitary gland are neuroectodermal in origin, possibly glial in nature.
176 citations
••
TL;DR: Experimental studies suggest that TUDCA may have cytoprotective and anti‐apoptotic action, with potential neuroprotective activity, in patients with amyotrophic lateral sclerosis.
Abstract: Background and purpose Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead-in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) slope during the treatment period compared to the lead-in phase]. Secondary outcomes included between-treatment comparison of ALSFRS-R at study end, comparison of the linear regression slopes for ALSFFRS-R mean scores and the occurrence of adverse events. Results Tauroursodeoxycholic acid was well tolerated; there were no between-group differences for adverse events. The proportion of responders was higher under TUDCA (87%) than under placebo (P = 0.021; 43%). At study end baseline-adjusted ALSFRS-R was significantly higher (P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group (P Conclusions This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS.
176 citations
••
TL;DR: The present 11th E BC consensus document represents the summary of the up-to-date EBC consensus and recommendations and points to the fact that there is a multitude of strategies and approaches to bifurcation stenting within the provisional strategy and in the different two-stent strategies.
Abstract: Coronary bifurcations are involved in 15-20% of all percutaneous coronary interventions (PCI) and remain one of the most challenging lesions in interventional cardiology in terms of procedural success rate as well as long-term cardiac events. The optimal management of bifurcation lesions is, despite a fast growing body of scientific literature, the subject of considerable debate. The European Bifurcation Club (EBC) was initiated in 2004 to support a continuous overview of the field, and aims to facilitate a scientific discussion and an exchange of ideas on the management of bifurcation disease. The EBC hosts an annual, compact meeting, dedicated to bifurcations, which brings together physicians, engineers, biologists, physicists, epidemiologists and statisticians for detailed discussions. Every meeting is finalised with a consensus statement which reflects the unique opportunity of combining the opinions of interventional cardiologists with the opinions of a large variety of other scientists on bifurcation management. The present 11th EBC consensus document represents the summary of the up-to-date EBC consensus and recommendations. It points to the fact that there is a multitude of strategies and approaches to bifurcation stenting within the provisional strategy and in the different two-stent strategies. The main EBC recommendation for PCI of bifurcation lesions remains to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. The consensus document covers a moving target. Much more scientific work is needed in non-left main (LM) and LM bifurcation lesions for continuous improvement of the outcome of our patients.
176 citations
Authors
Showing all 13795 results
Name | H-index | Papers | Citations |
---|---|---|---|
Peter J. Barnes | 194 | 1530 | 166618 |
Cornelia M. van Duijn | 183 | 1030 | 146009 |
Dennis R. Burton | 164 | 683 | 90959 |
Paolo Boffetta | 148 | 1455 | 93876 |
Massimo Antonelli | 130 | 1272 | 79319 |
David B. Audretsch | 126 | 671 | 72456 |
Piero Anversa | 115 | 412 | 60220 |
Marco Pahor | 112 | 476 | 46549 |
David L. Paterson | 111 | 739 | 68485 |
Alfonso Caramazza | 108 | 451 | 39280 |
Anthony A. Amato | 105 | 911 | 57881 |
Stefano Pileri | 100 | 635 | 43369 |
Giovanni Gasbarrini | 98 | 894 | 36395 |
Giampaolo Merlini | 96 | 684 | 40324 |
Silvio Donato | 96 | 860 | 41166 |